Business Wire

Future Scientists From Europe Shine in Global Cambridge Schools Science Competition

10.7.2025 08:45:00 CEST | Business Wire | Press Release

Share

Three student teams from schools across Europe have won awards in the 2025 Cambridge Science Competition, run by the International Education group at Cambridge University Press & Assessment (Cambridge). The winning teams are from Türkiye, Ukraine, and Czech Republic and were selected by an expert panel of judges at the University of Cambridge for the high calibre of their projects, each of which aim to tackle real-world sustainability issues.

The global Cambridge Science Competition, an extracurricular program for students aged 14–16, fosters a passion for innovation, research and critical thinking while honing practical lab skills. Participants are challenged to design projects with real-world relevance to their schools or communities, focusing on sustainability. This year, the competition saw record entries from student teams who are studying for Cambridge IGCSE science qualifications, taught across 6,000 schools globally.

Best in Europe winner – Türkiye

Students from Beştepe College in Türkiye took the top European prize for a pioneering investigation into the use of pinecone-derived probiotics to improve bean crop yields. By creating biodegradable probiotic beads, the team demonstrated a remarkable 105% increase in bean plant growth over 20 days. Their research could suggest a sustainable, low-cost alternative to chemical fertilizers.

Ilgın Yıldırım Usta, IGCSE Biology Teacher, said: “This project was more than just science—it became a chance for us to connect with something bigger: our responsibility to the environment and the future of agriculture.”

Student, Ece Aydın, added: “This experience has inspired me to keep asking questions, stay curious, and continue working on solutions that can help both people and the planet.”

Team photo available here.

Country Award - Ukraine

A team of students from Gymnasium A+ school in Ukraine earned a Country Award for developing biodegradable bioplastics from brown seaweed. Their eco-friendly material offers a flexible, rapidly decomposing alternative to single-use plastics, addressing a pressing environmental issue.

Student, Amina Sorochynska said: “Winning a prize in this competition feels amazing. We’re passionate about environmental issues and wanted to find a biodegradable alternative to plastic. It’s great to know that our idea was thought to be potentially so useful.”

Team photo available here.

Country Award - Czech Republic

Students from Townshend International School in the Czech Republic also received a Country Award for their study of moss species’ ability to absorb water and filter pollutants.

Their project showed how mosses could be used to combat drought and improve water quality, offering a natural bio-filtration and conservation solution.

Student Abigail said: “After winning, I feel much more confident in my abilities to problem-solve and design solutions. This experience has motivated me to take on more science projects in the future.”

Team photo available here.

Christine Ozden, Global Director for Climate Education at Cambridge, said: “These students are a shining example of what’s possible when young minds are given the opportunity to explore science in creative, meaningful ways. These three outstanding projects show how Cambridge students across Europe are using science to address real-world challenges. What unites them is not only great scientific thinking and application, but a deep sense of responsibility toward shaping a better future.”

For more information about the competition, visit Cambridge Science Competition winners 2025.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250709046784/en/

Contacts

Media contact
Dr Karen Birmingham
Head of Communications
International Education, Cambridge University Press & Assessment
karen.birmingham@cambridge.org

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye